SANTA MONICA, California, 6 October 2020 / PRNewswire / – The search for an effective therapeutic intervention for dementia has sparked interest in the class of drugs known as tyrosine kinase inhibitors (TKIs). TKIs demonstrate the potential to reduce inflammation, improve the disposal of damaged cells and accelerate the removal of toxic proteins that build up with dementia and related disorders. More recently, it has also been suggested that this class of drugs may inhibit the initial aggregation of toxic proteins that cause such disorders in the first place.
Sheldon Jordan, MD, Chief Investigator for The Regenesis Project, conducted a multi-institutional study to evaluate the efficacy of one TKI in particular, bosutinib in the treatment of early forms of dementia. This study specifically used a Pfizer drug, Bosulif (generic name bosutinib) that had previously been approved by the Food and Drug Administration (FDA) for the treatment of chronic leukemia.
In collaboration with Dr. Santosh kesari at the Pacific Neuroscience Institute, an affiliate of Providence Health Systems, and a number of independent neurology clinics, thirty-one patients with probable Alzheimer’s dementia or Parkinson’s spectrum disorder with dementia completed 12 months of bosutinib therapy and an additional 12 months follow-up.
Initially, the study was designed to see if TKI like bosutinib could prevent further memory loss or worsening of dementia over time. Surprisingly, Bosulif actually produced a significant improvement of an entire level of dementia on the clinical dementia rating scale, (as estimated by the Quick Dementia Rating System [QDRS]) in nearly half of people taking this drug over the course of a year. Further investigation of bosutinib as a therapeutic agent for dementia will be conducted by the Regenesis project.
For more information on this study, refer to the research published in the online September 2020 issue of Neurology® Clinical practice, an official journal of the American Academy of Neurology or visit www.neurologysantamonica.com.